Fenoldopam is a dopamine D1 receptor agonist used for the short term management of hypertension. It lowers blood pressure through arteriolar vasodilation.
- Mechanism
- Curator reviewed
Fenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α or β -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
- Primary indication
- For the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.Curator reviewed · 2 structured indications
- Formula / weight
- C16H16ClNO3 · 305.756 g/mol (avg)
- First approval
- United States, 2004
- Code names
- SKF 82526 · SKF 82526-J
- Brand names
Resolves to
TVURRHSHRRELCG-UHFFFAOYSA-NSMILESOC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12What you can answer from here — as of September 23, 2026
Which drugs share a target with Fenoldopam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account